The Power to Deliver

logo

We are proud to announce the transition of Dendreon to a standalone company. Through this transition, we look forward to building on the great progress we’ve made in the effort to help more men with advanced prostate cancer live longer.

discover how

discoverhow

important safety information

INDICATION

PROVENGE® (sipuleucel-T) is a prescription medicine that is used to treat certain patients with advanced prostate cancer. PROVENGE is made from your own immune cells.

IMPORTANT SAFETY INFORMATION

  • Before getting PROVENGE, tell your doctor about all your medical problems, including problems with your heart or lungs, or if you have had a stroke
  • Tell your doctor about all the medicines you take, including prescription and nonprescription drugs, vitamins, and dietary supplements
  • PROVENGE is made from your own immune cells, collected approximately 3 days before each scheduled infusion of PROVENGE. The collection is called “leukapheresis” (pronounced loo-kuh-fuh-REE-sis). You will get PROVENGE in 3 intravenous infusions (put into your veins), about 2 weeks apart. Each infusion takes about 60 minutes. You will then be monitored for at least 30 minutes. Your doctor will give you a schedule for your cell collection and infusion appointments. It is very important that you arrive on time for your appointments
  • The most common side effects of PROVENGE include chills, fatigue, fever, back pain, nausea, joint ache, and headache. These are not all the possible side effects of PROVENGE treatment
  • PROVENGE infusion can cause serious reactions. Tell your doctor right away if you:
    • Have breathing problems, chest pains, racing heart or irregular heartbeats, high or low blood pressure, dizziness, fainting, nausea, or vomiting after getting PROVENGE. Any of these may be signs of heart or lung problems
    • Develop numbness or weakness on one side of the body, decreased vision in one eye, or difficulty speaking. Any of these may be signs of a stroke
    • Develop symptoms of thrombosis which may include: pain and/or swelling of an arm or leg with warmth over the affected area, discoloration of an arm or leg, unexplained shortness of breath, chest pain that worsens on deep breathing
    • Get a fever over 100°F, or redness or pain at the infusion or collections sites. Any of these may be signs of infection
  • Tell your doctor about any side effect that concerns you or does not go away. For more information, talk with your doctor

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for full Prescribing Information.

Opportunity

As a company, we plan to focus on our priorities of expanding access to PROVENGE® (sipuleucel-T), both in the United States and around the world, conducting further clinical studies, and investigating personalized immunotherapies for other forms of cancer.

Reach More Patients


Expanding access to PROVENGE in the US and entering new global markets.

Support Clinical Studies


Investigating clinical applications for PROVENGE in earlier-stage prostate cancer.

Expand Therapies


Building on our success and developing our therapeutic platform for other oncology indications.

Commitment

We are committed to improving the lives of men living with prostate cancer, with the goal of ultimately helping to cure it altogether. Our new path ahead will allow us to accelerate our efforts, reach more patients, and invest in further research.

How do we assist Healthcare Professionals?

Partnerships are necessary in the fight against cancer. We stand behind the medical community by providing personalized immunotherapy to deploy as they seek to deliver the best care for their patients.

How do we help patients?

To date, more than 20,000 men with metastatic, late-stage prostate cancer have been treated with PROVENGE. We’re driven to expand access to more patients and, potentially, to those in earlier stages of the disease.

Operations

During and following this transition, Dendreon will continue to operate with the current leadership, manufacturing, operations, scheduling, R&D, and sales teams remaining in place. These teams proved instrumental in turning the business around, and will continue to play critical roles going forward.

Additionally, there will be no disruption or changes to the company’s technology, manufacturing, operations, or distribution process. Product for the United States will continue to be made in the USA.

Our core leadership team:

James Caggiano

Chief Executive Officer

Matthew Kemp

Chief Commercial Officer

Christina Yi

Chief Operations Officer

Get In Touch

Have questions? Looking for more information? Please send inquiries to: corporate.communications@dendreon.com

© 2017 Dendron Pharmaceuticals LLC.    All rights reserved.